C
Cellcolabs
Biotech & Life Sciences · Solna kommun, Sweden · Founded 2021
S a biotech impact startup on a mission to use advanced cell therapies to disrupt healthcare as we know it through efficient large-scale production of mesenchymal stem cells MoreLess
Cellcolabs, founded in 2021 and based in Stockholm, Sweden, specializes in the industrial GMP (Good Manufacturing Practice) production of high-quality Mesenchymal Stromal Cells (MSCs). These cells have regenerative, immunomodulatory, and anti-inflammatory properties, which could potentially cure or prevent many chronic diseases. The company aims to make MSCs available at scale to accelerate stem cell research and facilitate the development of future treatments. Cellcolabs does not provide treatments directly but sponsors or partners with clinical studies, offering updates on participation opportunities. The company serves researchers and healthcare providers in the advanced cell therapy market. Its business model revolves around the large-scale production and distribution of MSCs, generating revenue through sales to research institutions and clinical partners. Cellcolabs is committed to transforming healthcare and improving lives through advanced cell therapies.
Keywords: Mesenchymal Stromal Cells, GMP production, regenerative medicine, immunomodulatory, anti-inflammatory, chronic diseases, stem cell research, clinical studies, advanced cell therapy, healthcare transformation.
Company overview
Cellcolabs company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Solna kommun, Sweden
- Employees
- 78
- Open positions
- 3
- Dealroom signal
- 36.2
Valuation & funding
Cellcolabs funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $12M | $48M | Titan Capital | ↗ |
| EARLY VC✓Equity / VC | Mar 2024 | $8.7M | $35M | Undisclosed | ↗ |
| ANGEL✓Equity / VC | Mar 2022 | $7.7M | $31M | Ash Pournouri · Fredrik Jung-Abbou · Johannes Schildt · Fredrik Hjelm | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $2.1M | 0% | −$11M | -539.8% |
| 2025 | $2.1M | 0% | −$11M | -539.8% |
| 2024 | $2.1M | +159.2% | −$11M | -539.8% |
| 2023 | $794K | +7029.4% | ||
| 2022 | $11K | — | ||
| 2021 | — | — |
Growth signals
Cellcolabs website traffic
Latest recorded traffic for Cellcolabs is 3K monthly website visits, up 76.5% over the last three months. Cellcolabs's team declined 7.1% over the past year.
Hiring
Open positions at Cellcolabs
Current openings linked to this company in Dealroom.
Comparisons
Cellcolabs compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Cellcolabs's talent
Source: Dealroom Talent Intelligence.
Investors
14 investors on Cellcolabs's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Cellcolabs has talent and traffic
team presence
In the news
Latest news about Cellcolabs
Recent press, funding announcements, and product moves mentioning Cellcolabs — open to read from the original sources.
Market sentiment
What the market is saying about Cellcolabs
An AI-synthesized read of the highest-engagement posts about Cellcolabs on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellcolabs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.